Literature DB >> 16182208

Assessment of the feasibility of oral controlled release in an exploratory development setting.

Avinash G Thombre1.   

Abstract

Controlled release (CR) formulations have generally been considered as follow-ons to conventional immediate release formulations to manage the life cycle of a product. Although significant opportunities exist to use CR as an enabling technology for certain exploratory drug candidates, they have not been fully exploited. However, progress made in assessing CR feasibility based on the physicochemical and biopharmaceutical properties of the drug, together with advances made in understanding the various CR technologies and developing formulations in a fast and efficient manner, have increasingly made it possible to consider CR in an exploratory development setting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16182208     DOI: 10.1016/S1359-6446(05)03551-8

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  6 in total

1.  Biopharmaceutical Evaluation and CMC Aspects of Oral Modified Release Formulations.

Authors:  Rong-Kun Chang; Neil Mathias; Munir A Hussain
Journal:  AAPS J       Date:  2017-07-05       Impact factor: 4.009

2.  Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept.

Authors:  Jacob P R Jacobsen; Adrianna Oh; Rachel Bangle; Wendy L Roberts; Elizabeth L Royer; Nathan Modesto; Sonora A Windermere; Zixuan Yi; Rebecca Vernon; Manuel Cajina; Nikhil M Urs; Joshua C Snyder; Peter J Nicholls; Benjamin D Sachs; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2019-04-29       Impact factor: 7.853

Review 3.  Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.

Authors:  Jacob P R Jacobsen; Andrew D Krystal; K Ranga R Krishnan; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2016-09-28       Impact factor: 14.819

4.  SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept.

Authors:  Jacob Pr Jacobsen; Meghan L Rudder; Wendy Roberts; Elizabeth L Royer; Taylor J Robinson; Adrianna Oh; Ivan Spasojevic; Benjamin D Sachs; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2016-03-02       Impact factor: 7.853

5.  Pharmacokinetics and Pharmacodynamics of Immediate- and Modified-Release Mycophenolic Acid Preparations in Healthy Beagle Dogs.

Authors:  Michael Klotsman; Sebastien Coquery; Gayatri Sathyan; Vatsala Naageshwaran; Paddy Shivanand; Amanda J Fairchild; Oliver A Garden; Wayne H Anderson
Journal:  Front Vet Sci       Date:  2021-01-28

6.  Evaluation of the drug solubility and rush ageing on drug release performance of various model drugs from the modified release polyethylene oxide matrix tablets.

Authors:  Saeed Shojaee; Ali Nokhodchi; Mohammed Maniruzzaman
Journal:  Drug Deliv Transl Res       Date:  2017-02       Impact factor: 5.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.